Skip to content
Screener

4D Molecular Therapeutics FDMT Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$15.4B-739%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$431.9M-674%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$75.1M+55.4%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Regenxbio logo
RegenxbioRGNX
$65.93M+147%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$561.97M+119%
Enterprise value$510.02M+152%
P/S6.4×-7,758×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211939
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Purchases of marketable securities(33,519)(134,077)
Maturities of marketable securities102,396166,656
Disposal (acquisition) of property and equipment11(631)
Net cash provided by investing activities68,88831,948
Cash flows from financing activities
Issuance of common stock upon exercise of stock options1,674
Issuance of common stock under the ATM offering program, net of issuance costs9,810
Net cash provided by financing activities11,484

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is 4D Molecular Therapeutics's investing cash flow?
4D Molecular Therapeutics (FDMT) reported investing cash flow of $68.89M in Q1 2026.
How has 4D Molecular Therapeutics's investing cash flow changed year-over-year?
4D Molecular Therapeutics's investing cash flow increased by 115.6% year-over-year, from $31.95M to $68.89M.
What is the long-term trend for 4D Molecular Therapeutics's investing cash flow?
Over 3 years (2021 to 2025), 4D Molecular Therapeutics's investing cash flow has grown at a -18.6% compound annual growth rate (CAGR), from -$172.68M to -$92.97M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about 4D Molecular Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude